PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12, ...
PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo
PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...
GlobalData on MSN4d
PDS Biotechnology commences trial for head and neck squamous cell carcinoma
PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...
PDS Biotech Leadership to Participate in March Conferences
Versamune ® is a registered trademark of PDS Biotechnology Corporation. Investor Contact: Mike Moyer LifeSci Advisors Phone +1 (617) 308-4306 Email: [email protected] ...
PDS Biotech gets IND application clearance for colorectal cancer treatment
PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...
Morningstar3d
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...
Morningstar7d
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...
PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research note published on Friday,Benzinga reports. They currently have a $21.00 target price on ...
manilatimes7d
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech” or the "Company”), a late-stage immunotherapy company focused on transforming how the ...